MARKET

ONCY

ONCY

Oncolytics Biotech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.510
-0.120
-4.56%
After Hours: 2.520 +0.01 +0.40% 17:54 11/24 EST
OPEN
2.630
PREV CLOSE
2.630
HIGH
2.779
LOW
2.380
VOLUME
2.28M
TURNOVER
--
52 WEEK HIGH
6.02
52 WEEK LOW
0.9400
MARKET CAP
108.68M
P/E (TTM)
-3.2217
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Eli Lilly, Incyte Press Release Confirms FDA Issued Emergency Use Authorization For Distribution Of Baricitinib In Combo With Remdesivir For Confirmed COVID-19 Patients Who Require Oxygen Or Ventilator
Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the distribution and emergency use of
Benzinga · 5d ago
Oncolytics Biotech Reports Results From ReoGlio Phase 1b Trial Evaluating Combination Of Pelareorep, Granulocyte-Macrophage Colony-Stimulating Factor With Chemoradiotherapy
Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage
Benzinga · 5d ago
Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The results, which were featured in a podium presentation at the 2020 Society of Neuro-Oncology Annual Meeting, show a compelling signal of efficacy and demonstrate the safety and tolerability of the pelareorep-based combination therapy in newly diagnosed GBM patients.
PR Newswire · 5d ago
Oncolytics Biotech To Present AWARE-1 Data, Provide Updates On Phase 2 BRACELET-1 And IRENE Trials At The 2020 San Antonio Breast Cancer Symposium
Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium SAN DIEGO, Calif. and CALGARY, Alberta, Nov. 17,
Benzinga · 11/17 14:07
Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium
Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of three abstracts for electronic poster presentations to be given as part of the 2020 San Antonio Breast Cancer Symposium, which is being held virtually from December 8-11, 2020.
PR Newswire · 11/17 14:05
Oncolytics Biotech EPS misses by $0.06
Oncolytics Biotech (ONCY): Q3 GAAP EPS of -$0.16 misses by $0.06.As of September 30, 2020, the Company reported $26.7 million in cash and cash equivalents. The Company raised $3.6 million
Seekingalpha · 11/11 21:02
Oncolytics Biotech, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 11, 2020 / Oncolytics Biotech, Inc.
ACCESSWIRE · 11/11 20:15
TWTR, PINS, OSTK and TPR among premarket gainers
Universal Security Instruments (UUU) +87%.Cellect Biotechnology (APOP) +36%.Pinterest (PINS) +31% on Q3 results.Inphi Corporation (IPHI) +27% as the company will be acquired by Marvell in a cash and stock transaction.Xtant Medical Holdings (XTNT) +22% on Q3
Seekingalpha · 10/29 12:23
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONCY. Analyze the recent business situations of Oncolytics Biotech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONCY stock price target is 6.76 with a high estimate of 8.46 and a low estimate of 4.615.
EPS
Institutional Holdings
Institutions: 52
Institutional Holdings: 1.24M
% Owned: 2.87%
Shares Outstanding: 43.30M
TypeInstitutionsShares
Increased
7
151.21K
New
10
-44.20K
Decreased
7
111.54K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
0.00%
Key Executives
Chairman/Independent Director
Wayne Pisano
President/Chief Executive Officer/Director
Matthew Coffey
Chief Financial Officer/IR Contact Officer
Kirk Look
Corporate Executive
Andrew Guttadauro
Vice President
Allison Hagerman
Other
Rita Laeufle
Other
Michael Moore
Independent Director
Deborah Brown
Independent Director
Angela Holtham
Independent Director
Leonard Kruimer
Independent Director
William Rice
Independent Director
Bernd Seizinger
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ONCY
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Oncolytics Biotech, Inc. (USA) stock information, including NASDAQ:ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.